anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Despite advances in HIV care associated with HAART, many patients on HAART regimens develop physical and metabolic problems, including changes in body fat distribution (lipodystrophy), osteopenia and osteoporosis, dyslipidemia, and hyperlactatemia. Early studies suggest that protease inhibitors (PIs) were directly responsible for HIV Lipodystrophy Syndrome (HLS) and skeletal complications in HAART-treated patients. This study will compare HIV infected, HAART-treated children and youth and their uninfected counterparts to make connections between HAART, HLS, and skeletal and metabolic problems. The study is the first to address the prevalence and risk assessment of these complications in children, and will be useful in predicting long-term prognosis in HIV patients who use or have used HAART.

There will be three groups in the study. Group 1 participants will be uninfected volunteers who will receive no protocol-specific treatment or other intervention. Vertically infected HIV patients in Groups 2 and 3 will continue their current HAART either on a non-PI-containing regimen (Group 2) or a PI-containing regimen (Group 3). Screening evaluations will be conducted within 30 days prior to study entry. Study evaluations may be completed at study entry or over the course of up to 3 study visits. All participants will undergo whole body and regional DEXA scans (to assess bone density), measurements to determine sexual maturity, and blood work.
This will be a parallel-group randomized controlled trial with intention to treat analysis conducted via tele rehabilitation in Brazil. Two hundreds elderly people with chronic low back pain (except low risk on STartback screening tool) will be randomized to receive CFT (2 individualized sessions and 4-8 group sessions) or group Pilates (6-10 sessions) up to 12 weeks treatment. Participants will be assessed at baseline, post-intervention (12 weeks) 24 and 48 weeks after randomization. The trial will include cost-effectiveness and cost-utility analyses. Data of quality of life, healthcare costs, patient and family costs, and absenteism costs will be collected. The cost-effectiveness analysis will be performed using disability and pain intensity as outcomes. Costs and quality-adjusted life years will be used to calculate cost-utility.

Three qualitative studies will be conducted during the trial. The first will be performed by means of the interviews with a subsample of the participants before randomization. The aim will be to investigate how elderly people with chronic low back pain perceive their condition. The second will be performed by means of the analysis of a subsample of video recordings of CFT treatments. The aim will be to investigate the narratives of elderly people with chronic low back pain during CFT treatment sessions. The third will be performed after the last follow up by means of an interview with a subsample of participants that received CFT treatment. The aim will be to investigate the perceptions of elderly people with chronic low back pain about the impact of CFT via telerehabilitation.
Treatment Period 1: Subjects were admitted to the clinical unit on Day 1. Subjects received a single oral dose of BIA 5-1058 400 mg (4 x 100 mg tablets) on Day 1 after an overnight fast of at least 8 hours. Subjects were discharged from the clinical unit on Day 4 (approximately 72 hours after dosing) barring any medical reasons for an extended clinical stay.
MicroRNAs are involved in breast cancer development and progression, holding potential as biomarkers and therapeutic targets or tools. The roles of miR-20a-5p, a member of the oncogenic miR-17-92 cluster, remain poorly understood in the context of breast cancer. In this study, we elucidate the role of miR-20a-5p in breast cancer by examining its associations with breast cancer risk factors and clinicopathological features, and its functional roles in vitro. Tissue microarrays from 313 CAMO cohort breast cancer surgical specimens were constructed, in situ hybridization was performed and miR-20a-5p expression was semiquantitatively scored in tumor stromal fibroblasts, and in the cytoplasm and nuclei of cancer cells. In vitro analysis of the effect of miR-20a-5p transfection on proliferation, migration and invasion was performed in three breast cancer cell lines. High stromal miR-20a-5p was associated with higher Ki67 expression, and higher odds of relapse, compared to low expression. Compared to postmenopausal women, women who were premenopausal at diagnosis had higher odds of high stromal and cytoplasmic miR-20a-5p expression. Cytoplasmic miR-20a-5p was significantly associated with tumor grade. In tumors with high cytoplasmic miR-20a-5p expression compared to low expression, there was a tendency towards having a basal-like subtype and high Ki67. In contrast, high nuclear miR-20a-5p in cancer cells was associated with smaller tumor size and lower odds of lymph node metastasis, compared to low nuclear expression. Transfection with miR-20a-5p in breast cancer cell lines led to increased migration and invasion in vitro. While the majority of our results point towards an oncogenic role, some of our findings indicate that the associations of miR-20a-5p with breast cancer related risk factors and outcomes may vary based on tissue- and subcellular location. Larger studies are needed to validate our findings and further investigate the clinical utility of miR-20a-5p.
BACKGROUND: Diagnostic rates and risk factors for the subsequent development of chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism (PE) are not well defined.
METHODS: Over a 10-year period (2010-2020), consecutive patients attending a PE follow-up clinic in Sheffield, UK (population 554 600) and all patients diagnosed with CTEPH at a pulmonary hypertension (PH) referral centre in Sheffield (referral population estimated 15-20 million) were included.
RESULTS: Of 1956 patients attending the Sheffield PE clinic 3 months following a diagnosis of acute PE, 41 were diagnosed with CTEPH with a cumulative incidence of 2.10%, with 1.89% diagnosed within 2 years. Of 809 patients presenting with pulmonary hypertension (PH) and diagnosed with CTEPH, 32 were Sheffield residents and 777 were non-Sheffield residents. Patients diagnosed with CTEPH at the PE follow-up clinic had shorter symptom duration (p<0.01), better exercise capacity (p<0.05) and less severe pulmonary haemodynamics (p<0.01) compared with patients referred with suspected PH. Patients with no major transient risk factors present at the time of acute PE had a significantly higher risk of CTEPH compared with patients with major transient risk factors (OR 3.6, 95% CI 1.11-11.91; p=0.03). The presence of three computed tomography (CT) features of PH in combination with two or more out of four features of chronic thromboembolic pulmonary disease at the index PE was found in 19% of patients who developed CTEPH and in 0% of patients who did not. Diagnostic rates and pulmonary endarterectomy (PEA) rates were higher at 13.2 and 3.6 per million per year, respectively, for Sheffield residents compared with 3.9-5.2 and 1.7-2.3 per million per year, respectively, for non-Sheffield residents.
CONCLUSIONS: In the real-world setting a dedicated PE follow-up pathway identifies patients with less severe CTEPH and increases population-based CTEPH diagnostic and PEA rates. At the time of acute PE diagnosis the absence of major transient risk factors, CT features of PH and chronic thromboembolism are risk factors for a subsequent diagnosis of CTEPH.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine, neurology section and can find application in neurologic and neural rehabilitation clinic in treating the patients with aphasia. That is ensured by administration of acatinol memantin according to certain schedule with underlying logopedic lessons. Within the first week of therapy, the dose is 5 mg/day in the morning at mealtime. Within the second week, the dose is 10 mg/days, with 5 mg in the morning and in the evening. Within the third week, the dose is increased to 15 mg/days, with 10 mg in the morning and 5 mg in the evening. Within the fourth week, the dose is increased to 20 mg/days. And the maintenance dose makes 20 mg/days. ^ EFFECT: method provides effective treatment of apparent rough aphasia caused by disordered cerebral blood flow. ^ 1 ex, 2 tbl
PURPOSE:To collect a novel substance from a culture of a strain of the genus Pereniporia and utilize the substance in the fields of agricultural chemicals and medicines in searching for substances having the plant growth inhibitory action and antibiotic substance action. CONSTITUTION:A fungus producing a novel antibiotic substance No.8345-A, e.g. Pereniporia medullaepanis AJ8345 (FERM-P No.8181), of the genus Pereniporia is cultivated in a culture medium containing a carbon source, nitrogen source, inorganic salt, etc. in which general basidiomycetes are grown, under aerobic conditions. The substance No.8345-A is separated from the resultant culture by using the extraction method, chromatographic method, etc. The properties of the collected substance No.8345-A are as follows; White amorphous powder. Molecular formula: C15H24O4. Melting point; 150-158 deg.C. Soluble in methanol and ethyl acetate and slightly soluble in water. Exhibiting color reactions, e.g. positive to potassium permanganate and negative to ninhydrin.
OBJECTIVES: Primary objectives were to determine the relationship between prevalence of symptom documentation and intervention provision, and increasing severity of bothersome symptoms, as identified by guardians using guardian-reported Symptom Screening in Pediatrics Tool (proxy-SSPedi), which is validated and measures the extent of bothersome symptoms in paediatric patients with cancer.
METHODS: We included guardians of children 2-7 years of age receiving cancer treatments and seen in hospital daily for 4 consecutive days. Guardians reported proxy-SSPedi at study enrolment and 3 days later. Chart review was performed between the day prior and the day following proxy-SSPedi completion. Symptom documentation and intervention provision were determined by two independent abstractors.
RESULTS: We enrolled 190 guardians who provided 371 proxy-SSPedi assessments in 190 children. The most common severely bothersome symptoms were 'feeling tired', 'feeling more or less hungry than they usually do' and 'feeling cranky or angry'. Among those with increasing severity of bother, documentation was significantly more common for 12 symptoms while intervention was significantly more common for 7 symptoms. Intervention was not significantly more common with increasing severity of bother due to 'feeling tired', 'feeling more or less hungry than they usually do' and 'feeling cranky or angry'.
CONCLUSIONS: Symptom documentation was generally more common in patients with severely bothersome symptoms. Intervention was not more common among those with increasing severity of bother due to fatigue, changes in hunger or anger, which were the most common severely bothersome symptoms. Future efforts should focus on facilitating intervention provision to patients with bothersome symptoms.
FIELD: medicine, homeopathy, ophthalmology. SUBSTANCE: the innovation deals with homeopathic preparations used in the field of ophthalmology in treating myopia of I, II and III degree. It is suggested to apply preparation containing Acidum phosphoricum, Cuprum metallicum, Gelsemium, Magnesia phosphorica taken in equal ratios at C6 dilution, moreover, this preparation is designed in the form of sugar granules. It has no side effects, contraindications for usage, it could be combined with other therapeutic methods and preparations and could be, also, applied in monotherapy. EFFECT: higher efficiency of therapy. 1 cl, 2 ex, 1 tbl
Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
Disclosed are embodiments of a method of using mustard meal or mustard meal extract. Certain embodiments concern controlling vegetable sprouting, such as potato sprouting. Vegetables, such as potatoes, may be exposed to products resulting from mustard meal, or an extract thereof, contacting water. Other embodiments concern a process for controlling plant pests, such as insects, nematodes, fungi, weeds, and combinations thereof, with specific embodiments being particularly useful for weed suppression. Certain embodiments comprise extracting glucosinolates from plant material, or processed plant material, selected from the family Brassicaceae, particularly from the genera Brassica and Sinapis. Extracted glucosinolates can be hydrolyzed to form active compounds, or alternatively, they can be hydrolyzed in situ, by simultaneously or sequentially applying myrosinase. The extract can be applied to plants, to the soil adjacent to the plant.
In a contact-free health monitoring system using a wearable device and a contact-free health monitoring method using the same, the health monitoring system includes a wearable device, a communication network, a data server, a monitoring unit, and a data generation unit. The wearable device is mounted on or attached to a wearer and collects biosignals and location information of the wearer. The communication network transmits the information collected from the wearable device by wire or wirelessly. The data server stores the collected information transmitted through the communication network. The monitoring unit calls the information stored in the data server and displays the same to the outside. The data generation unit generates statistical data by integrating health conditions and location information of the wearers based on the stored information or the displayed information. The health monitoring system enables contact-free health monitoring and statistical management of the related information.
Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Gastrointestinal Toxicity: GI toxicity is the dose-limiting toxicity of orally-administered brincidofovir. Signs of GI toxicity include decreased body weight and food consumption, fecal changes (absent, nonformed, or liquid feces), and dehydration. Dose-limiting GI events, diagnosed as gastropathy and enteropathy or enteritis, were observed following daily oral administration of brincidofovir in mice and monkeys. A single dose study to characterize the pathological dynamics of GI toxicity and potential reversibility revealed a dose responsive enteritis in rats, which reversed in surviving animals by 14 days post-dose. Subsequent animal studies used twice weekly oral administration to reflect anticipated clinical use and no dose-limiting GI toxicity was observed.

Aminotransferase Elevations: Increases in ALT (2- to 5-fold) were observed in both rodent and nonrodent species in nonclinical toxicology studies of orally administered brincidofovir. The changes seen with oral dosing appeared with highest frequency in monkeys, followed by mice and then rats. ALT elevations did not correlate with dose concentration and reversed after cessation of dosing. There were no gross or microscopic hepatic changes that correlated with the ALT increases.
PURPOSE: A method for preparing amorphous adefovir dipivoxil solid dispersion with improved stability is provided to ensure high elution rate and to prevent or treat chronic hepatitis type B. CONSTITUTION: An adefovir dipivoxil solid dispersion with improved stability contains adefovir dipivoxil and hydrophilic polymer. Adefovir dipivoxil solid dispersion is amorphous. A method for preparing adefovir dipivoxil solid dispersion comprises: a step of completely dissolving adefovir dipivoxil and hydrophilic polymer in a solvent; and a step of drying the solution to preparing a solid dispersion. An oral solid formulation for treating acute hepatitis type B contains adefovir dipivoxil solid dispersion. The oral solid is granule or tablet.
The COVID-19 pandemic has given rise to post-acute cognitive symptoms, often described as 'brain fog'. To comprehensively grasp the extent of these issues, we conducted a study integrating traditional neuropsychological assessments with experimental cognitive tasks targeting attention control, working memory, and long-term memory, three cognitive domains most commonly associated with 'brain fog'. We enrolled 33 post-COVID patients, all self-reporting cognitive difficulties, and a matched control group (N = 27) for cognitive and psychological assessments. Our findings revealed significant attention deficits in post-COVID patients across both neuropsychological measurements and experimental cognitive tasks, evidencing reduced performance in tasks involving interference resolution and selective and sustained attention. Mild executive function and naming impairments also emerged from the neuropsychological assessment. Notably, 61% of patients reported significant prospective memory failures in daily life, aligning with our recruitment focus. Furthermore, our patient group showed significant alterations in the psycho-affective domain, indicating a complex interplay between cognitive and psychological factors, which could point to a non-cognitive determinant of subjectively experienced cognitive changes following COVID-19. In summary, our study offers valuable insights into attention challenges faced by individuals recovering from COVID-19, stressing the importance of comprehensive cognitive and psycho-affective evaluations for supporting post-COVID individuals.
While conspiracy theories are treated as irrational fringe beliefs in popular culture, conspiracy belief is quite common. Given the disconnect between stereotypes about conspiracy belief and its prevalence, I tested whether people have difficulty recognizing the conspiracy theories that they believe as conspiracy theories. Across two studies I demonstrate that people have considerable difficulty identifying conspiracy theories they believe as conspiracy theories, particularly when they do not take much time to consider whether their beliefs might be conspiracy theories. This is consistent with the notion that people experience "conspiracy blindness." People have trouble recognizing the conspiracy theories they believe as conspiracy theories because they do not take the time to consider whether their beliefs might be conspiracy theories. In Study 2, I demonstrate that people can overcome their conspiracy blindness and recognize the conspiracy theories they believe as conspiracy theories when they are given a definition for "conspiracy theory" and asked to consider their answer. This suggests that people are typically ignorant of their own conspiracy beliefs, but capable of recognizing them when given the tools and motivation to do so. However, recognizing their beliefs as conspiracy theories does not reduce their adherence to those beliefs.
Squamous cell lung cancer (SCLC) occurs as a result of dysregenerative changes in the bronchial epithelium: basal cell hyperplasia (BCH), squamous cell metaplasia (SM), and dysplasia. We previously suggested that combinations of precancerous changes detected in the small bronchi of patients with SCLC may reflect various "scenarios" of the precancerous process: isolated BCH→stopping at the stage of hyperplasia, BCH+SM→progression of hyperplasia into metaplasia, SM+dysplasia→progression of metaplasia into dysplasia. In this study, DNA methylome of various forms of precancerous changes in the bronchial epithelium of SCLC patients was analyzed using the genome-wide bisulfite sequencing. In BCH combined with SM, in contrast to isolated BCH, differentially methylated regions were identified in genes of the pathogenetically significant MET signaling pathway (RNMT, HPN). Differentially methylated regions affecting genes involved in inflammation regulation (IL-23, IL-23R, IL12B, IL12RB1, and FIS1) were detected in SM combined with dysplasia in comparison with SM combined with BCH. The revealed changes in DNA methylation may underlie various "scenarios" of the precancerous process in the bronchial epithelium.
Chronic effects of non- invasive ventilation on myocardial function in patients with obesity hypoventilation syndrome (OHS) are scarcely understood. The aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (BiPAP) on cardiac parameters and myocardial biomarkers in patients with OHS. Clinically stable patients with OHS referred to the tertiary centre for the initiation of long-term BiPAP therapy were consecutively enrolled in the study. At baseline, all participants underwent overnight cardiorespiratory polygraphy. BiPAP therapy using volume-targeted spontaneous/timed mode delivered via an oro-nasal mask was initiated. Beat-to-beat noninvasive monitoring by impedance cardiography was used to assess heart function at baseline and after 3 and 12 months of BiPAP use. Serum troponin 1, N-Terminal Pro-B-Type Natriuretic Peptide (NTProBNP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) were monitored. Potential risks and benefits comprise haemodynamic effects of NIV on cardiovascular parameters including cardiac output and stroke volume. The study started 06/2016 and enrolment was finalized in October 2018. The study was funded by grants from the Slovak Research and Development Agency under contract No. APVV-16-0158, and VEGA 1/0220/17 and 1/0393/22 of the Ministry of Education, Slovakia. The main investigator is Pavol Pobeha, MD, PhD, co author is Ivana Paranicova, MD, PhD and the corresponding author (study coordinator prof. Ruzena Tkacova, MD, PhD)
The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. the helicase activity requires ATP and divalent cations such as Mg?2+ and Mn2+¿. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.